ARS Pharmaceuticals, Inc. SPRY Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s enterprise value?
- ARS Pharmaceuticals, Inc. (SPRY) reported enterprise value of $869.56M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s enterprise value changed year-over-year?
- ARS Pharmaceuticals, Inc.'s enterprise value decreased by 27.2% year-over-year, from $1.19B to $869.56M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s enterprise value?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s enterprise value has grown at a -0.3% compound annual growth rate (CAGR), from $1.22B to $1.21B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.